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Parathyroid hormone prevents 1,25 (OH)2D3 induced down-regulation
of the vitamin D receptor in growth plate chondrocytes in vitro.
I,25(OH)2D1 has an antiproliferative effect on growth plate chondrocytes
when given in high doses, whereas low doses stimulate chondrocyte
proliferation. In the present in vitro study we investigated the effects of
parathyroid hormone (PTI-l) when given concomitantly with 1,25(OH)2D3
on cell proliferation and vitamin D receptor (VDR) regulation. Freshly
isolated rat tibial chondrocytes were grown in monolayer cultures or in
agarose stabilized suspension cultures (10% charcoal-treated FCS). VDR
expression was determined by RT-PCR generating a 297 hp fragment and
by binding assays (Scatchard analysis) with [3H]-1,25(OH)2D3. Cell pro-
liferation was measured by [3H]-thymidinc incorporation, growth curves in
monolayer cultures and by colony formation in agarose-stabilized suspen-
sion cultures. Optimal concentration of 1,25(OH)2D3 (10_12 M) and of
PTH fragments [hPTI-I(1-34) or hPTH(28—48), lO° M] showed additive
effects on DNA synthesis of and colony formation by growth plate
chondrocytes. This may be explained in part by an up-regulation of VDR
by PTH: PTH increased both mRNA expression of VDR and binding
capacity. 1,25(OH)2D3 (10—12 M) induced an up-regulation of the VDR
within 24 hours followed by a down-regulation after incubation for more
than 24 hours. PTH fragments added concomitantly prevented the down-
regulation seen with 1,25(OH)2D3. These findings provide evidence that
PTH is a growth promoting hormone that also modulates the effects of
1,25(OH)2D1 by regulating the VDR status of 1,25(OH)2D3 target cells.
In children with chronic renal failure, disturbed vitamin D
metabolism and secondary hyperparathyroidism contribute to
growth failure [1—3]. 1,25(OH)2D3 and parathyroid hormone(PTH) interact to form an endocrine fcedback mechanism:
1,25(01 {)2D suppresses mRNA for pre-pro-PTI-f [4, 51 and
inhibits proliferation of parathyroid cells 16]. Conversely, PTH is
a potent stimulator of renal la-hydroxylasc [7].
PTH and I ,25(OH)2D3 control growth by their direct actions on
bone and cartilage cells [8—131. In earlier studies, we demon-
strated that 1,25(OH)2D3 had a biphasic effect on proliferation of
growth cartilage cells; proliferation is stimulated by l,25(OH)7D3
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at a concentration of 10_12 M, but not at high concentrations
(l0 M) [9]. Long-term exposure of growth cartilage cells to
1,25(OH)2D results in a homologous down-regulation of the
VDR [14]. This effect may potentially reduce the biological
activity of 1,25(OH)2D3 on its target cells.
In the present study we investigated whether PTH is able (i) to
overcome the I ,25(OH)2D3-induced down-regulation of the VDR
in growth plate chondrocytes, and (ii) to modulate the effect of
1,25(OH)7D3 on DNA synthesis and colony formation by chon-
drocytes.
METHODS
Materials
1 ,25(OH)2-[26,27-methyl-3H]cholecalciferol (158 Ci/mmol) was
obtained from Amersham Buehler (Braunschweig, Germany);
unlabeled la,25(OH)2D7, 25(OH)D3 were gifts from Dr. Calcanis
and Dr. Uskokovic (Hoffmann-La Roche, Germany and USA);
hydroxyapatite, dithiothreitol, Triton X-100, were from Sigma
Chemical Co. (Munich, Germany); F-12 medium, DMEM (Dul-
becco's modified minimal essential medium), PBS (phosphate
buffered saline), gentamicin sulphate, clostridium collagenase
(EC 3.4.24.3), DNAse I (EC 3.1.21.1), and trypan blue were from
Boehringer (Mannheim, Germany). The bovine PTH-fragment
(1-34) [bPTH(1-34)] were from Bissendorf-Biochemicals (Han-
foyer, Germany), the human PTH-fragment (28-48) [hPTH(28-
48)] was synthesized at the Gesellschaft für Biotechnologischc
Forschung, Braunschweig, Germany [10]. Standard tow (SL)- and
Low gel temperature (LGT)-agarose was purchased from BioRad
(Richmond, VA, USA). FCS was from Seromed (Berlin, Germa-
ny); Primers and Superscript II reverse transcriptase were pur-
chased from Gibco BRL (Eggenheim, Germany). 1 ,25(OH)2D in
FCS determined by radioimmunoassay [15] was 1.1 X 10'° M;
Charcoal treatment reduced 1a,25(OH)2D concentrations below
the detection limit of the I a,25(OH)2D3 assay (2.4 X lO M).
PTH related peptide (PTHrP) in charcoal-stripped FCS was 9,8
pg/mI (radioimmunoassay, Fa. Immundiagnostik, Bensheim, Ger-
many).
Cell cultures
Isolation of chondrocytes. Epiphyseal chondrocytes from 80 g
Sprague-Dawley rats (Charles River, Kieslegg, Germany) were
45
46 Klaus et al: PTH regulation of vitamin D receptor
isolated and cultured with a modified method of Benya and
Shaffer [16] as described [9]. In brief, the epiphyseal growth plates
(tibia) were cleaned of perichondrium and dissected microscopi-
cally by a transverse cut through the calcification zone and by
separation from the epiphysis with a scalpel, carefully avoiding
any loss of cartilage close to the bony epiphysis.
Pooled growth plates from 5 (monolayer or agarose stabilized
suspension cultures) or 10 (VDR-assays) animals were digested
for three hours at 37°C by clostridial collagenase (0.12% wt/vol,
Fa. Boehringer) and 0.02% wt/vol bacterial DNAse (Fa. Boehr-
inger) in F-12/DMEM i/i medium. After isolation cells were
washed three times in serum free medium. Viability, determined
by the trypan blue exclusion technique, always exceeded 90%.
Dissociated cells were counted using a Neubauer chamber (W.
Schreck, Hofheim, Germany).
Monolayer cultures. Cells were cultured in 60 mm plastic wells
(Falcon Labware, Oxnard, CA, USA) for proliferation assays and
in 100 mm dishes for VDR-determination using F-12/DMEM 1/1
medium, supplemented with 50 j.tg/ml L-ascorbic acid, 10 mmol/
liter HEPES, 100 tg/ml gentamicin and 10% fetal calf serum
(FCS) or 10% charcoal-stripped FCS (Ch-FCS) at 37°C, gassed
with 95% air/5% CO2. The nominal calcium concentration,
measured with an ion-selective electrode of a Fresenius lonom-
eter EF (Fresenius, Oberursel, Germany) was 1.2 mmol/liter.
PTH-fragments dissolved in phosphate buffered saline (PBS)
and/or vitamin D mctabolites dissolved in ethanol or vehicle
control (ethanol, 0.05% final concentration) were added with
fresh medium every other day unless otherwise stated, Cells
reached a saturation density of 1.2 X i0 cells/cm2.
Agarose stabilized suspension cultures
Cells were cultured in agarose according to Benya and Schaffer
[16] as described [9]. Sixty mm Petri dishes were coated with a
bottom film of 1% standard low (SL) agarose in water. The
agarose was autoclaved (110°C, 45 mm) before coating and was
allowed to solidify at room temperature. Low gel temperature
(LGT) agarose was autoclaved as above, and mixed with an equal
volume of double concentrated F-12/DMEM 1/1 medium to give
a final concentration of agarose of 1%. The cells were diluted with
F-12/DMEM 1/1 medium, containing 10% Ch-FCS at 37°C to a
final concentration of 160,000 cells/ml. This cell suspension was
then mixed with 1% LGT agarose (37°C) to give a final cell
concentration of 80,000 cells/mI in 0.5% LGT. Precoated dishes
were heated to 37°C before 2 ml of the LGT-cell suspension were
added. Dishes were kept at 37°C for 10 minutes before gelation
was obtained at 4°C (10 mm). Subsequently, 3 ml F-12/DMEM 1/1
medium supplemented with 10% Ch-FCS and various concentra-
tions of PTH-fragments and/or vitamin D metabolites (or solvent
control) as indicated, were added on top of the gelated agarose.
Medium was changed every other day. The cultures were screened
for adherent cell clusters of more than five cells. No such clusters
were seen at the start of culture in any experiment presented in
this study.
Immunocytology for PCNA. Freshly isolated chondrocytes were
plated on glass slides in 35 mm dishes in F-12/DMEM 1/1
medium, nominal calcium concentration 1.2 mmol/liter supple-
mented with 10% FCS. Medium was changed every other day,
until cells reached subconfluency (day 4). For synchronization of
cell cycles, cells were kept in serum-free F-12/DMEM 1/1 medium
for 24 hours as described [9]. Thereafter the medium was changed
to F-12/DMEM 1/1, 1.2 mmol/liter calcium supplemented with
10% Ch-FCS. bPTH(1-34) was added for the first six hours of the
culture period, followed by thoroughly washes with medium and a
postincubation in the absence of bPTH(1-34). Under these con-
ditions, best results with respect to PTH-driven [3H]-thymidine-
incorporation were obtained [13]. The expression of PCNA
(proliferating cell nuclear antigen) was examined in cells fixated in
formalin (3.7%, 7 mm). Afterwards the specimen was bathed in
Carnoy sp. (ethanol/acetate 2/1 vol/vol) for five minutes, followed
by three washes with PBS. The rabbit anti mouse monoclonal
antibody E-413 (Fa. DAKO, Denmark) was diluted 1:400. Visu-
alization was obtained by the streptavidin-biotin method as de-
scribed [171.
Assays of chondrocyte growth and proliferation
Radiothymidine incorporation. Incorporation of [3H]-thymidine
into DNA was determined as radioactivity in TCA-precipitable
material as described [91. Prior to the start of experiments cells
were synchronized by maintaining them under serum free condi-
tions for 24 hours. Medium was changed (10% Ch-FCS) and
hormones or solvent added as indicated for 8 to 48 hours. Two
Ci of [3H]-thymidine were added for the last four hours. Cells
were counted in parallel cultures.
Colony formation in agarose stabilized suspension cultures. Sus-
pension cultures were terminated by fixation in buffered formal-
dehyde (4%). Colonies were counted in 100 squares (2 mm grid)
for each dish. A cell colony was defined as a cluster of more than
five cells. For easier identification of colonies, the formed matrix
was stained by alcian blue under acidic condition as described [9,
181. These staining technique visualizes glycoaminoglycans. Data
are given as colony count and as cloning efficiency, that is, colonies
formed per 1000 seeded cells.
RT-PCR
RNApreparation. Total cellular RNA was collected to examine
the expression of VDR receptor. Total RNA from cultured cells
was isolated by the RNA-Clean® method (Angewandte Gentech-
nologie Systeme, Heidelberg, Germany) following the instructions
of the manufacturers.
RT-PCR amplification of VDR. RT and PCR primers were
deduced from rat VDR sequence [19]. Two micrograms of total
RNA were reverse transcribed into cDNA with Superscript
reverse transcriptase and specific primers for VDR (Ri, 5'-
CCGAACACCTCCAGCACAAG-3'). After eDNA synthesis, ex-
cess primers were removed and PCR amplification was performed
using the cDNA template with the specific primers pairs (Fl,
5'-GCCCACCACAAGACCTAT-3'; and R2, 5'-CClTI'TG-
GAT-GCTGTAACTG-3'). The amplification profile in a Perkin
Palmer Gene Amp PCR System 9600 consisted of denaturation at
94°C for 30 seconds, annealing at 56°C for 30 seconds, and
extension at 72°C for 30 seconds for all primers after a five-minute
denaturation step at 94°C. The 32 cycle amplified products (297
bp for VDR) were detected by electrophoresis in a 2% agarose gel
and visualized by ethidium bromide staining and ultraviolet
transillumination. As control, -actin mRNA was also reverse
transcribed using specific primer (RI, 5'-CTAGAAGCATTT-
GCGGTCGGAC-3') and the resulting cDNA amplified with the
primers -actin Ri and -actin Fl (5'-CATCACCATFG-
GCAATGAGCG-3') following the same protocol resulting in a
PCR product of 405 bp. Control reactions performed by omitting
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Table 1. Effect of bPTH(1-34), 1,25(OH)2D1 and their combination on
radiothymidinc incorporation in monolayer cultures
1,25(OH)2D1 bPTH(1-34) Radiothymidine incorporation
added added % of solvent control
Solvent 100 13
105 12
162 lSa.h
143 9°
200
154 6°
93 5
257 15u,d
226 15"'"
120 13
Cell cycles of subconfluent chondrocyte cultures were synchronized by
incubation in serum-free medium for 24 hours. After changing the
medium to F12/DMEM 1/1 with 10% Ch-FCS, bPTH(1-34) was added at
indicated concentrations for 6 hours. After three washes, postincubation
was performed in the absence of bPTH(1-34) for 42 hours. Cells stimu-
lated with 1,25(OH)2D3 (102 M to 10 M) with or without PTH were
incubated with the steroid hormone for the total culture period, that is,
1,25(OH)2D3 was again added after the washes. Radiothymidine was
added for the last 4 hours of the 48 hour incubation period. Statistics are
by ANOVA, N = 8 per group.
P < 0.01 vs. solvent control
< 0.01 vs. bPTH l0- M
"P < 0.01 vs. 1,25(OH)2D1 10_lI M
dp < 0.01 vs. 1,25(OH)2D3 10-12 M and bPTH(1-34) i0° M
"P <0.01 vs. 1,25(OH)2D3 lO M and bPTH(1-34) 10 M
reverse transcriptase or template RNA showed no reaction prod-
uct. The optic densities of the VDR product was normalized for
the density of 13-actin by a commercially available computer
software program (Bio-ID V.96.; Vilber, Lourmat, France).
Assay of 1,25(OH)2D3 receptor (VDR) activity
KTED extracts. Cell extracts were prepared as described else-
where [201. In brief, cell suspensions (1 x io cells/mi) were
homogenized in 0.4 M KTED buffer (0.4 M KC1, 10 mM Tris HC1,
1,5 mM EDTA, 2 mvt dithiothreitol, 10 m sodium molybdate, pH
7,4). A purified fraction was prepared by centrifugation at 205,000
g for 30 minutes using a Ti-50 rotor (Beckman Instruments,
Fullerton, CA, USA). The supernatant was used for binding
studies.
Scatchard analysis. Saturation analysis according to Scatchard
(21] was carried out as described [9]. One hundred microliter
aliquots (protein concentration 0.5 to 1 .2 mglml) were incubated
for 16 hours at 4°C with increasing concentrations (0.1 to 7.0 nM)
of [3H]-1,25(OH)2D3 in the absence or presence of 100-fold molar
excess of 1,25(OH)2D3. Bound [31-l]-1,25(OH)2D3 was deter-
mined using the hydroxyapatite assay [22].
Statistics
Data are given as mean SD. Statistical analysis was carried out
using ANOVA or the Mann-Whitney-U-test as appropriate with a
commercial available PC-software (Statgraph Plus, Statgraphics
Cooperation, USA and Sigma Stat, Jansen, Germany). Statistical
significance was considered for P < 0.05.
Hormone added
Colony formation
% of
solvent control
Cloning efficiency
colonies/1000
seeded cells
A
Solvent control 100 11.7 1.14 0.24
1,25(OH)2D3 10_12 M
1,25(OH)2D-, 10—m M
164 21.6'
87.9 20.3
1.87 0.40"
0.99 0.20
1,25(OH)2D1 i0- M 82.0 22.6 0.94 0.20
1,25(OH)2D3 10' M 73.8 19.4 0.84 0.16
B
Solvent control 100 14.5 0.91 0.06
bPTH(,1-34) 10'° M
bPTH(l-34) iO M
187 14.3"
162 6.2°
1.71 0.03k
1.47 006h
bPTH(1-34) 10 M 128 9.4 1.16 0.08
C
100 15.6 1.27 0.21
152 14.2" 1.75 0.25"
149 10.8" 1.85 0.20"
194 10.9"'" 2.75 t).30"-"
RESULTS
Effect of bPTH(1.34), 1,25(OH)2D3 or their combination on
radiothymidine incorporation in monolayer and cloning
efficiency in agarose-stabilized suspension cultures
Monolayer cultures (Table 1). Bovine PTH(1-34) dose-depen-
dently stimulated radiothymidine incorporation in monolayer
cultures of growth plate chondrocytes with an optimal effect
at 100 M. Higher concentrations were less stimulatory.
1,25(OH)2D3 modulated radiothymidine incorporation in a bi-
phasic manner: low concentrations (10--- 12 M) increased DNA
synthesis, whereas concentrations of i0 M or higher showed
an inhibitory effect. The biphasic effect was noted when
1,25(OH)2D3 was added to medium supplemented with 10%
charcoal-stripped FCS or to serum-free medium (data not
shown), demonstrating that a very low concentration (10— 12 M) of
1,25(OH)2D3 is effective for stimulation of DNA synthesis. Coin-
cubation of bPTH(1-34) (10° M) and 1,25(OH)2D3 (1012 M to
iO' M) yielded additive effects on radiothymidine incorporation
for the stimulatory concentrations of 1,25(OH)2D5 (1012 M to
10 10 M); the high dose of 1,25(OH)2D3 (10 M) inhibited not
only basal radiothymidine incorporation, but also the effect of the
PTH fragment (Table 1).
Agarose stabilized suspension cultures (Table 2). In parallel to
results obtained in the monolayer culture system, 1,25(OH)2D3
showed a biphasic effect on colony formation in agarose stabilized
suspension cultures: a stimulation of colony formation (and
cloning efficiency) was seen with 10 12 M 1,25(OH)2D1, whereas
higher concentrations up to i0 M tended to inhibit colony
formation; however, this inhibitory effect narrowly missed statis-
tical significance (Table 2). Bovine PTI-I(i-34) showed the highest
cloning efficiency for 10 M with a monotonous decrease for
higher concentrations (Table 2). In the following experiments,
the optimal stimulatory concentrations of bPTH(1-34) and
1,25(OH)2D1, that is, 10 10 M and 10— 12 54, respectively, were
used. When chondrocytes were coincubated with bPTH(1-34)
Table 2. Effect of bPTH(1-34), 1,25(OH)2D3 and their combination on
colony formation and cloning efficiency
10-12 M
I0" M
i0 M
I0_2 M
M
108 M
Solvent
10-12 M
10—10 MiO
i0° M
iO M
10—0 M
Solvent control
l,25(OH)2D3 10 -12 M
bPTH(1-34) 10b0 M
1,25(OH)2D-, + bPTH(1-34)
"P < 0.03 vs. solvent control
1'P < t).0l vs. solvent control
"P < 0.01 vs. la,25(OH)2D3 or bPTH(1-34), respectively
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Fig. 1. Effect of bPTH(1-34) on expression of
PCNA in chondrocytes. Subconfiuent
chondrocyte cultures were kept in serum-free
F-12/DMEM 1/1 medium for 24 hours for
synchronization of cell cycles. Thereafter
medium was changed to F-12/DMEM 1/1, 1.2
mmol/liter calcium supplemented with 10% Ch-
FCS. (.4) Bovine PTH(1-34) was added for the
first six hours of the culture period, followed by
thoroughly washes with medium (10% Ch-FCS)
and a post-incubation in the absence of
bPTH(1-34) up to 48 hours. (B) Solvent control
cells (10% Ch-FCS); cultures received the same
washings parallel to group A. PCNA was
stained immunocytochemically as described in
Methods (original magnification X360).
Fig. 2. Stimulation of specific binding of
[3H1-1,25(OH)2D1 by incubation of
chondrocytes with 1,25(OH)2D3 (10—12 M) and/
or bPTH(1.34) (10° M) after 48 hours of
incubation. (A) Subconfiuent chondrocytes,
synchronized by preculture in serum-freeB medium for 24 hours [and by implication in the
absence of 1,25(OH)2D3] were cultured in F-12/
DMEM 1/1 medium, 1.2 mmol nominal calcium
concentration with 10% Ch-FCS. 1,25(OH),D3
(102 vi final concentration) or bPTH(1-34)
(10'° vi) were added for the entire 48-hour
culture period. Specific binding of [3H]-
1,25(OH)2D3 was determined in KTED whole
cell extracts as described in the Methods
section. (B) The Scatchard plot shows increased
specific binding capacity (intercept on the
abscissa) with exposure to the hormones
without any change in affinity (slope) Nmax
solvent control 2751 bound molecules/cell,
1,25(OH)2D3 2889; bPTH(1-34) 7577;
1,25(OH)2D1 + bPTH(1-34) 7839; Kd 2.7 X
10_b M, 3.4 X 1010 M, 2.4 X 10—10 M and0 0 '+1) QU 4.5 X 10 M, respectively. Symbols are: (A)
2 bPTH(1-34); (V) bPTH(1-34) + 1, 25(OH)D3;10 molecules/cell (0) continuous 1,25(OH)2D3; (•) control.
A
C')0
C\J
,— II)
C') 12
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0
50
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(10b0 M) and I,25(OH)2D3 (10_12 M) an additive effect on
cloning efficiency was demonstrable (Table 2).
Modulation of 1,25(OH)2D3-receptor expression by bPTH(1-34),
1,25(OH)2D3 or their combination
For the determination of VDR expression the monolayer
culture technique was used. In these cultures, bPTH(I-34) stim-
ulated proliferation of the majority of cultured chondrocytes and
not only a subgroup, as shown by expression of PCNA (Fig. 1).
The effect of bPTH(l-34) 10 10 M on specific binding of
[3H]-i,25(OH)2D3 was measured in purified KTED whole cell
extracts of subconfluent chondrocytes. Bovine PTH(1-34) in-
creased maximal specific binding (N) three- to fourfold versus
solvent control after 48 hours (Fig. 2). This increase in VDR was
time dependent, reaching a plateau level after 24 hours (Fig. 3).
The increased persisted for at least 48 hours (Fig. 3). The
apparent dissociation constant (Kd) was similar in all groups
[solvent control, 4.2 X 10 '° vi; bPTH(l-34) 8 hr, 2.2; bPTH(1-34)
12 hr, 2.2; bPTH(1-34) 24 hr, 2.1; bPTH(1-34) 48 hr, 3.31. The
up-regulation of the VDR on binding levels was dependent on
transcriptional and translational processes, because the bPTH(1-
34) driven increase in specific binding of [3H]-1,25(OH)2D3 was
obliterated by actinomycin D (2 j.g/ml) and cycloheximide (5
g/ml), respectively [solvent control 2678 bound molecules/cell;
bPTH(1-34) 10 10 M 7839; actinomycin D (2 j.rg/ml) 2915; bPTH
(1-34) + actinomycin D 3971; cycloheximide (2 ig/m1) 3015;
bPTH(1-34) + cycloheximide 3080], without change in affinity
(data not given).
1,25(OH)2D3 (10— 12 M) showed a time-dependent biphasic
effect on VDR expression in cultured chondrocytes. Within the
first 24 hours it increased specific binding of [3H]-1,25(OH)2D3
(Figs. 2 and 3). The maximal binding capacity was reached after 24
hours; with prolonged incubation with 1,25(OH)2D3 (10_12 M) for
more than 24 hours, the binding of [3H]-1,25(OH)2D3 decreased
to basal levels. Chondrocytes were vital according to trypan blue
exclusion tests at all time points studied. The apparent loss of
Control PTH 1 ,25(OH)2D3
+PTH -PTH
aS a vi:Ce en
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Fig. 3. Time course of 1,25(OH)2D3 receptor expression by cultured
chondrocytes: Effects of 1,25(OH)2D3, bPTH(l.34) and their combination.
Subconfiuent chondrocytes, synchronized by preculture in serum-free
medium for 24 hours were cultured in F-12/DMEM 1/1 medium, 1.2 mmol
nominal calcium concentration with 10% Ch-FCS. 1,25(OH)2D3 (10-12 M
final concentration) or bPTH(1-34) (10° M final concentration) or their
combination were added for the indicated culture periods. Specific binding
of [3H}-1,25(OH)2D3 was determined in KTED whole cell extracts at
indicated intervals. The graph shows specific binding of [3H]-1,25(OH)2D3
as a function of duration of incubation. Dissociation constants, Kd, were
similar in all groups. Symbols are: (0) control; (•) 1,25(OH)2D3; (V)
PTH; (•) PTH + 1,25(OH)2D3.
binding capacity with prolonged incubation with i,25(OH)2D3
was not due to an increase of occupied receptors, because
addition of i0 M 1,25(OH)2D3 during the last hour of incuba-
tion period did not affect Nmax nor change Kd (data not given).
In contrast, continuous coincubation of chondrocytes with
bPTH(1-34) 10_laM and 1,25(OH)2D3 102 M up-regulated the
VDR to a similar level as each of the two hormones alone after 24
hours (Figs. 2 and 3). However, for prolonged incubation periods,
coincubation with both hormones resulted in a persistent up-
regulation of VDR up to 48 hours (Fig. 3).
The effect of bPTH(1-34) (10— 1(1 M) and 1,25(OH)2D1 (10 -12
M) or their combination on VDR mRNA is shown in Figure 4.
RT-PCR yielded a 297 bp amplification product for the VDR
mRNA and a 405 bp product for 13-actin mRNA (Fig. 4B). A
significant increase of VDR mRNA was observed after 24 hours
incubation with bPTH(1-34), regardless whether coincubated with
1,25(OH)2D3 (10_12 M) or not. In the group treated with
l,25(OH)2D3 (10_12 M), no difference in VDR mRNA levels were
found at 24 hours compared to control levels (Fig. 4A).
DISCUSSION
The present study confirms that 1,25(OH)2D3 is stimulatory on
DNA synthesis of and colony formation by chondrocytes at low
concentrations and is inhibitory at high concentrations [9]. These
concentrations of 1,25(OH)2D3 are effective not only in 10%
charcoal-stripped FCS hut also in serum-free medium (data not
shown).
PTH as well as 1,25(OH)2D3 have stimulatory effects on
chondrocytes as evidenced by (i) increased DNA synthesis (radio-
thymidine incorporation in monolayer cultures) and (ii) increased
cloning efficiency (that is, colony formation in agarose stabilized
suspension cultures). Maximal effective concentrations were iden-
tical to those established previously in dose response studies for
cell proliferation in a monolayer culture system [9, 13, 14] using
aminoterminal [bPTH(1-34)] and mid-regional PTH fragments
VDR (297 bp)
13-actin (405 bp)
Fig. 4. Regulation of VDR mRNA by bPTH(1-34), 1,25(OH)2D3 and their
combination. Subconfiuent chondrocyte monolayer cultures were synchro-
nised in serum free medium for 24 hours. Medium was then changed to
F12/DMEM 1/1 containing 10% Ch-FCS. Cells were incubated with
bPTH(1-34) 10_la M, 1,25(OH)2D3 1012 M or both hormones for 24
hours. Thereafter, total RNA was prepared and mRNA levels encoding
the VDR were quantitated by RT-PCR assay as described in the Methods
section. (A) The graph illustrates up-regulation of the VDR mRNA by
bPTH(1-34) (10- M, PTH) and by concomitant incubation with
1,25(OH)2D1 (10— 2 M) and bPTH(1-34) (10° M). 1,25(OH)2D3 (10°
M) alone did not increase the amplification product after 24 hours. (B) The
RT-PCR amplification products are detected by electrophoresis in a 2%
agarose gel and visualized by ethidium bromide staining and ultraviolet
transillumination. Results are given as mean SCM of the VDR/-actin
mRNA ratio of three separate experiments. Statistics are by ANOVA.
*p < 0.05 versus control.
[hPTH(28-48)] and 1,25(OH)2D3, respectively. Coincubation with
both agonists at their optimal concentration (that is, 10_0 M
bPTH(1-34) and 102 M 1,25(OH)2D3, respectively) had additive
effects.
The mechanism responsible for delayed homologous down-
regulation of VDR is unknown, specifically whether the activity of
pre-existing receptor molecules is modulated (that is, phosphor-
ylation), whether VDR interacts with modulating proteins, or
whether VDR synthesis is altered on the postranscriptional level.
However, the missing up-regulation VDR mRNA concentrations
after 24 hours of incubation with 1,25(OH)2D3 indicate, at least in
part, a post-transcriptional mechanism. In other systems, that is,
fibroblasts and intestinal epithelial cells [23], transfected COS-
cells [24], and karatinocytes [25], post-transcriptional regulation
of VDR was demonstrated. Down-regulation of VDR may limit
the action of vitamin D, since it has been shown that the biological
activity of 1,25(OH)2D3 is proportional to VDR expression [26,
271. Irrespective of the mechanism involved, PTH reversed the
effect of 1,25(OH)2D3 on VDR expression, thus rendering possi-
ble increased biological activity of 1,25(OH)2D1.
Hyperparathyroidism contributes to the growth disturbance of
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uremic children. This is due to the destructive effect of excessive
PTH concentrations on metaphyseal cartilage and bone structure
that may automatically lead to epiphyseal slipping [1, 28]. This
effect contrasts with the action of more physiological concentra-
tions of PTH which are clearly stimulatory. This is shown by the
observation of short stature in hypoparathyroid subjects despite
adequate vitamin D treatment [29] and is complemented by in
vitro studies showing a stimulatory effect of PTH on growth
cartilage cells [10, 13].
Administration of vitamin D (metabolites) stimulates growth in
long-standing nutritional rickets and low-dosed active vitamin D
metabolites in calcitriol deficiency, that is, renal failure [3, 30—33].
This contrasts with the antiproliferative effect of high-dose
1,25(OH)2D3 on growth cartilage cells in vitro [9] and on abnor-
mal keratinocyte proliferation in psoriasis in vitro and in vivo [34,
351.
It has been discussed whether high-dose pulse therapy of
1,25(OH)2D3 has a growth depressing effect in uremic children
either by substantial lowering of PTH concentrations [36] or by
direct antiproliferative effects of 1,25(OH)2D3 on the growth
apparatus [9, 37]. The above observation would argue for caution
in using 1,25(OH)2D1 pulse therapy for treatment of renal
hyperparathyroidism in all uremic children. Studies to define the
optimal target PTH concentration are clearly required.
Our finding that PTH is able to maintain up-regulation of the
VDR irrespective of continuous exposure of cells to 1,25(OH)2D3
is of more general interest. Previously, we were able to demon-
strate that the temporal pattern of exposure of chondrocytes to
1,25(OH)2D3 influences VDR expression, an intermittent mode
of exposure maintaining a high VDR level in contrast to contin-
uous incubation with 1,25(OH)2D3 [141. We speculated that the
higher binding capacity for 1,25(OH)2D3 per cell may explain, at
least in part, the superior efficacy of intermittent exposure to
1,25(OH)2D3 with respect to suppression of secondary hyperpara-
thyroidism. Several groups determined the VDR status in animals
[38] and humans [39] with chronic renal failure. Different results
have been reported that are explained, at least in part, by
technical difficulties of measuring VDR & vivo [40]. None of the
investigators has taken into account so far that not only uremia,
the vitamin D status and circulating 1,25(OH)2D3, but also
circulating PTH contributes to regulation of the VDR.
In conclusion, PTH has stimulatory effects on growth cartilage
chondrocytes that are additive to those of 1,25(OH)2D3, and this
may be explained in part by up-regulation of the VDR. The effect
of PTH is time-dependent. This raises the issue of whether the
spacing of 1,25(OH)2D3 administration is important in uremic
children, a point of obvious importance for developing treatment
strategies for children with secondary renal hyperparathyroidism.
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